Transdermal Peptide TD-1 HCl is a novel peptide for enhanced transdermal drug delivery that facilitates the penetration of the skin barrier by several drugs and large hydrophilic proteins, such as insulin and human growth hormoneb.

In vitro, 0.5 mg/mL Transdermal Peptide TD-1 HCl markedly enhanced the transdermal penetration of curcumin liposomes (Cur-Lips) in mouse skin models (Qₙ = 2.20 μg/cm²/h), and maintained strong anti-melanoma activity even in the presence of 150 mM NaCl and serum. Transdermal Peptide TD-1 HCl combined with Cur-Lips significantly inhibited B16F10 melanoma cell proliferation (P < 0.001), while Transdermal Peptide TD-1 HCl alone showed no cytotoxicity at low concentrations[1].

In vivo, topical application of Transdermal Peptide TD-1 HCl (0.5 mg/mL) with Cur-Lips gel twice daily for 12 days significantly reduced tumor volume and weight in B16F10 melanoma-bearing mice (P < 0.001), induced tumor cell apoptosis, and downregulated serum VEGF levels[1].